Artemether: A new therapeutic strategy in experimental rheumatoid arthritis

Immunopharmacology and Immunotoxicology

Volumn 27, Issue 4, 2005, Pages 615-630

  Cuzzocrea, Salvatore ^a   Saadat, Farshid ^b   Di Paola, Rosanna ^a   Mirshafiey, Abbas ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anti inflammatory; Antimalarial Drugs; Artemether; Artemisinin; Immunosuppressive; Nitric Oxide; Rheumatoid Arthritis

Indexed keywords

ARTEMETHER; COLLAGEN TYPE 1; METHOTREXATE; NITRIC OXIDE SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCOMPATIBILITY; BONE EROSION; CELL INFILTRATION; CLINICAL EXAMINATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; FIBROSARCOMA; HISTOPATHOLOGY; KNEE; MALE; MOUSE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; RADIODIAGNOSIS; RAT; RHEUMATOID ARTHRITIS; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTIBODIES; ANTIMALARIALS; ANTIRHEUMATIC AGENTS; ARTEMISININS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BONE AND BONES; CELL LINE, TUMOR; CELL SURVIVAL; COLLAGEN TYPE II; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EDEMA; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAPERITONEAL; JOINTS; MALE; MATRIX METALLOPROTEINASE 2; METHOTREXATE; MICE; NITRIC OXIDE; RATS; RATS, INBRED LEW; TIME FACTORS;

ANIMALIA;

EID: 32344434505     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.1080/08923970500418786     Document Type: Article

References (58)

1. Efferth, T. Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy. Drug Resist. Updat. 2005, 8, 85-97.
2. Tan, R.X.; Zheng, W.F.; Tang, H.Q. Biologically active substances from the genus Artemisia. Planta Med. 1998, 64, 295-302.
3. Van der Meersch, H. Review of the use of artemisinin and its derivatives in the treatment of malaria. J. Pharm. Belg. 2005, 60, 23-29.
4. Haynes, R.K.; Chan, H.W.; Ho, W.Y.; Ko, C.K.; Gerena, L.; Kyle, D.E.; Peters, W.; Robinson, B.L. Convenient access both to highly antimalaria-active 10-arylaminoartemisinins, and to 10-alkyl ethers including artemether, arteether, and artelinate. Chembiochem. 2005, 6, 659-667.
5. Efferth, T.; Marschall, M.; Wang, X.; Huong, S.M.; Hauber, I.; Olbrich, A. Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses. J. Mol. Med. 2002, 80, 233-242.
6. Mahmoud, M.R.; Botros, S.S. Artemether as adjuvant therapy to praziquantel in murine Egyptian schistosomiasis mansoni. J. Parasitol. 2005, 91, 175-178.
7. Efferth, T.; Olbrich, A.; Bauer, R. mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether. Biochem. Pharmacol. 2002, 64, 617-623.
8. Klayman, D.L. Qinghaosu (artemisinin): an antimalarial drug from China. Science 1985, 228, 1049-1055.
9. Butler, A.R.; Wu, Y.L. Artemisinin (qinghaosu) - a new type of antimalarial drug. Chem. Soc. Rev. 1992, 21, 85-90.
10. Price, R.; van Vugt, M.; Nosten, F.; Luxemburger, C.; Brockman, A.; Phaipun, L.; Chongsuphajaisiddhi, T.; White, N. Artesunate versus artemether for the treatment of recrudescent multidrug-resistant falciparum malaria. Am. J. Trop. Med. Hyg. 1998, 59, 883-888.
11. Ribeiro, I.R.; Olliaro, P. Safety of artemisinin and its derivatives.. A review of published and unpublished clinical trials. Med. Trop. 1998, 58, 50-53.
12. De Vries, P.J.; Dien, T.K. Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. Drugs 1996, 52, 818-836.
13. Shen, W.J.; Thiero, M. Effects of combined artemether and dihydroartemisinin in treatment of children with falciparum malaria. Zhonghua Er. Ke. Za. Zhi. 2005, 43, 65-66.
14. Sutherland, C.J.; Ord, R.; Dunyo, S.; Jawara, M.; Drakeley, C.J.; Alexander, N.; Coleman, R.; Pinder, M.; Walraven, G.; Targett, G.A. Reduction of malaria transmission to anopheles mosquitoes with a six-dose regimen of co-artemether. Plo. S. Med. 2005, 2, e92.
15. Falade, C.; Makanga, M.; Premji, Z.; Ortmann, C.E.; Stockmeyer, M.; de Palacios, P.I. Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 2005, 99, 459-467.
16. Aceng, J.R.; Byarugaba, J.S.; Tumwine, J.K. Rectal artemether versus intravenous quinine for the treatment of cerebral malaria in children in Uganda: randomised clinical trial. Br. Med. J. 2005, 330, 317-318.
17. Wartenberg, M.; Wolf, S.; Budde, P.; Grunheck, F.; Acker, H.; Hescheler, J.; Wartenberg, G.; Sauer, H. The antimalaria agent artemisinin exerts antiangiogenic effects in mouse embryonic stem cell-derived embryoid bodies. Lab. Invest. 2003, 83, 1647-1655.
18. He, X.L.; Liu, Z. Protection of artesunate on activation and injury of vascular endothelial cells induced by lipopolysaccharide. Zhongguo Zhong Xi. Yi. Jie. He. Za. Zhi. 2004, 24, 1110-1113.
19. Kwiatkowski, D.; Bate, C. Inhibition of tumour necrosis factor (TNF) production by antimalarial drugs used in cerebral malaria. Trans. R. Soc. Trop. Med. Hyg. 1995, 89, 215-216.
20. Wu, G.D.; Zhou, H.J.; Wu, X.H. Apoptosis of human umbilical vein endothelial cells induced by artesunate. Vascul. Pharmacol. 2004, 41, 205-212.
21. Chen, H.H.; Zhou, H.J.; Fang, X. Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol. Res. 2003, 48, 231-236.
22. Sun, X.Z. Experimental study on the immunosuppressive effects of qinghaosu and its derivative. Zhong Xi. Yi. Jie. He. Za. Zhi. 1991, 11, 37-38.
23. Aldieri, E.; Atragene, D.; Bergandi, L.; Riganti, C.; Costamagna, C.; Bosia, A.; Ghigo, D. Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-κB activation. FEBS Lett 2003, 552, 141-144.
24. Cuzzocrea, S.; Mazzon, E.; Bevilaqua, C.; Costantino, G.; Britti, D.; Mazzullo, G.; De Sarro, A.; Caputi, A.P. Cloricromene, a coumarine derivative, protects against collagen-induced arthritis in Lewis rats. Br. J. Pharmacol. 2000, 131, 1399-1407.
25. Szabo, C.; Virag, L.; Cuzzocrea, S.; Scott, G.S.; Hake, P.; O'Connor, M. Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthetase. Proc. Natl. Acad. Sci. USA. 1998, 9, 3867-3872.
26. Bremell, T.; Abdelnour, A.; Tarkowski, A. Histopathological and serological progression of experimental Staphylococcus aureus arthritis. Infect. Immun. 1992, 60, 2976-2985.
27. Oliver, S.J.; Cheng, T.P.; Banquerigo, M.L.; Brahn, E. Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF). Cell. Immunol. 1995, 166, 196-206.
28. Mirshafiey, A.; Chitsaz, M.; Attar, M.; Mehrabian, F.; Razavi, A.R. Culture filtrate of Cryptococcus neoformans var. gattii (CneF) as a novel anti-inflammatory compound in the treatment of experimental septic arthritis. Scand. J. Immunol. 2000, 52, 278-284.
29. Cuzzocrea, S.; Costantino, G.; Mazzon, E.; Caputi, A.P. Beneficial effects of raxofelast (IRFI 016), a new hydrophilic vitamin E-like antioxidant, in carrageenan-induced pleurisy. Br. J. Pharmacol. 1999, 126, 407-414.
30. Heussen, C.; Dowdle, E.B. Electrophoretic analysis of plasminogen activator in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal. Biochem. 1980, 102, 196-202.
31. Harris, E.D. Rheumatoid arthritis: pathophysiology and implications for therapy.. N. Engl. J. Med. 1990, 322, 1277-1289.
32. Griffiths, M.M.; Eichwald, E.J.; Martin, J.H.; Smith, C.B.; DeWitt, C.W. Immunogenetic control of experimental type II collagen-induced arthritis. I. Susceptibility and resistance among inbred strains of rats. Arthritis Rheum. 1981, 24, 781-789.
33. Larsson, P.; Kleinau, S.; Holmdahl, R.; Klareskog, L. Homologous type II collagen-induced arthritis in rats: characterization of the disease and demonstration of clinically distinct forms of arthritis in two strains of rats after immunization with the same collagen preparation. Arthritis Rheum. 1990, 33, 693-701.
34. Stuart, J.M.; Townes, A.S.; Ang, A.H. The role of collagen autoimmunity in animals and human diseases. J. Invest. Dermatol. 1982, 79, 1-11.
35. Clague, R.B.; Morgan, K.; Shaw, M.J.; Holt, P.J. Native type II collagen-induced arthritis in the rat. II. Relationship between the humoral immune response to native type II collagen and arthritis. J. Rheumatol. 1980, 7, 775-782.
36. Takeshita, M.; Hinoue, H.; Furukawa, O.; Takata, I. Initial arthritic lesions induced by immunization with type II collagen in Lewis rats. Exp. Anim. 1995, 44, 63-66.
37. Takeshita, M.; Sugita, T.; Takata, I. Pathological evaluation of effect of anti-rheumatic drugs on type II collagen-induced arthritis in Lewis rats. Exp. Anim. 1997, 46, 165-169.
38. Holmdahl, R.; Andersson, M.; Goldschmidt, T.J.; Gustafsson, K.; Jansson, L.; Mo, J.A. Type II collagen autoimmunity in animals and provocations leading to arthritis. Immunol. Rev. 1990, 118, 193-232.
39. Weinblatt, M.E. Rheumatoid arthritis: treat now, not later. Ann. Intern. Med. 1996, 124, 773-774.
40. Boey, M.L. Treatment strategies in rheumatoid arthritis. Singapore Med. J. 1992, 33, 631-632.
41. Araiza-Casillas, R.; Cardenas, F.; Morales, Y.; Cardiel, M.H. Factors associated with chloroquine-induced retinopathy in rheumatic diseases. Lupus 2004, 13, 119-124.
42. Wassenberg, S.; Rau, R. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis. J. Rheumatol. 2003, 30, 1891-1892.
43. Johnsen, V.; Forre, O.; Haga, H.J.; Kvien, T.K.; Mikkelsen, K.; Nordvag, B.Y.; Rodevand, E. Combination therapy in rheumatoid arthritis. Tidsskr. Nor. Laegeforen. 2003, 123, 1511-1513.
44. Carmichael, S.J.; Charles, B.; Tett, S.E. Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther. Drug Monit. 2003, 25, 671-681.
45. Carmichael, S.J.; Beal, J.; Day, R.O.; Tett, S.E. Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate. J. Rheumatol. 2002, 29, 2077-2083.
46. Mauri, C.; Williams, R.O.; Walmsley, M.; Feldmann, M. Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur. J. Immunol. 1996, 26, 1511-1518.
47. Mussener, A.; Klareskog, L.; Lorentzen, J.C.; Kleinau, S. TNF-alpha dominates cytokine mRNA expression in lymphoid tissues of rats developing collagen and oil-induced arthritis. Scand. J. Immunol. 1995, 42, 128-134.
48. Ialenti, A.; Moncada, S.; Di Rosa, M. Modulation of adjuvant arthritis by endogenous nitric oxide. Br. J. Pharmacol. 1993, 110, 701-706.
49. Salvemini, D.; Wang, Z.Q.; Wyatt, P.S.; Bourdon, D.M.; Marino, M.H.; Manning, P.T.; Currie, M.G. Nitric oxide: a key mediator in the early and late phase of carrageenan-induced rat paw inflammation. Br. J. Pharmacol. 1996, 118, 829-838.
50. Terato, K.; Hasty, K.A.; Reife, R.A.; Cremer, M.A.; Kang, A.H.; Stuart, J.M. Induction of arthritis with monoclonal antibodies to collagen. J. Immunol. 1992, 148, 2103-2108.
51. Mattsson, L.; Lorentzen, J.C.; Svelander, L.; Bucht, A.; Nyman, U.; Klareskog, L.; Larsson, P. Immunization with alum-collagen II complex suppresses the development of collagen-induced arthritis in rats by deviating the immune response. Scand. J. Immunol. 1997, 46, 619-624.
52. Hitchon, C.A.; Danning, C.L.; Illei, G.G.; EI-Gabalawy, H.S.; Boumpas, D.T. Gelatinase expression and activity in the synovium and skin of patients with erosive psoriatic arthritis. J. Rheumatol. 2002, 29, 107-117.
53. Jackson, C.J.; Arkell, J.; Guyen, M. Rheumatoid synovial endothelial cells secrete decreased levels of tissue inhibitor of MMP (TIMP1). Ann. Rheum. Dis. 1998, 57, 158-161.
54. Dell'Eva, R.; Pfeffer, U.; Vene, R.; Anfosso, L.; Forlani, A.; Albini, A.; Efferth, T. Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xeno grafttumors by the anti-malarial artesunate. Biochem. Pharmacol. 2004, 68, 2359-2366.
55. Espevik, T.; Nissen-Meyer, J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J. Immunol. Methods. 1986, 95, 99-105.
56. Firestein, G.S. Invasive fibroblast-like synoviocytes in rheumatoid arthritis: passive responders or transformed aggressors?. Arthritis Rheum 1996, 39, 1781-1790.
57. Bucala, R.; Ritchlin, C.; Winchester, R.; Cerami, A. Constitutive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts. J. Exp. Med. 1991, 173, 569-574.
58. Cho, M.L.; Kim, W.U.; Min, S.Y.; Min, D.J.; Min, J.K.; Lee, S.H.; Park, S.H.; Cho, C.S.; Kim, H.Y. Cyclosporine differentially regulates interleukin-10, interleukin-15, and tumor necrosis factor αproduction by rheumatoid synoviocytes. Arthritis Rheum 2002, 6, 2-51.